![conference banner](/images/conference-banner.jpeg)
Abstract
Features of autoimmunity have been associated with both Alzheimers disease (AD) and with diabetes. In both diseases high levels of advanced glycation end products (AGEs) and their receptor (RAGE) have been detected in tissues and in the circulation. In addition high titers of antibodies directed against a RAGE-like peptide occur in the circulation. In this study we report the presence of auto-antibodies directed against RAGE and the cytotoxic amyloid peptide Aβ42 in plasma samples derived from four study groups. Anti-RAGE IgG titers were greatest in the AD-diabetic cohort. They were followed in decreasing order by the AD-non-diabetic cohort, the elderly diabetic cohort, and lastly by the control non-diabetic elderly cohort. The same profile of IgG differences was evident for the anti-Aβ42 titers. When all of the data were combined, there was a strong linear correlation between the RAGE and Aβ42 titers suggesting that the two peptides exist as a tight complex in plasma. Plasma IgG titers were not correlated with cognitive status except that AD and ADdiabetic participants were significantly cognitively impaired relative to the two non-AD groups. There also was no significant correlation between IgG titers and subject age, except that there was a trend for a negative slope for the AD participants and a positive slope for the control participants. In keeping with the human data, we also report that chemicallyinduced diabetes in rats was associated with high levels of AGEs, anti-RAGE-like IgGs, and anti-Aβ42-like IgGs. For non-diabetic rats, there was a clear age-dependency regarding the magnitude of the IgG levels. These data support the concept of an interrelationship between diabetes and AD. For both diseases one underlying contributing factor to cytotoxicity could be the development of an autoimmune response triggered by the presence of AGEs and amyloid peptides.
Keywords: Diabetes, anti-RAGE, AD-non-diabetic cohort, plasma IgG levels, anti-Ab42 IgG markers
Current Alzheimer Research
Title: Autoimmunity in Alzheimers Disease as Evidenced by Plasma Immunoreactivity Against RAGE and Aβ42: Complication of Diabetes
Volume: 3 Issue: 3
Author(s): Shyamala Mruthinti, Rosann F. Schade, Dean U. Harrell, Nidhi K. Gulati, S. Swamy-Mruthinti, Gregory P. Lee and Jerry J. Buccafusco
Affiliation:
Keywords: Diabetes, anti-RAGE, AD-non-diabetic cohort, plasma IgG levels, anti-Ab42 IgG markers
Abstract: Features of autoimmunity have been associated with both Alzheimers disease (AD) and with diabetes. In both diseases high levels of advanced glycation end products (AGEs) and their receptor (RAGE) have been detected in tissues and in the circulation. In addition high titers of antibodies directed against a RAGE-like peptide occur in the circulation. In this study we report the presence of auto-antibodies directed against RAGE and the cytotoxic amyloid peptide Aβ42 in plasma samples derived from four study groups. Anti-RAGE IgG titers were greatest in the AD-diabetic cohort. They were followed in decreasing order by the AD-non-diabetic cohort, the elderly diabetic cohort, and lastly by the control non-diabetic elderly cohort. The same profile of IgG differences was evident for the anti-Aβ42 titers. When all of the data were combined, there was a strong linear correlation between the RAGE and Aβ42 titers suggesting that the two peptides exist as a tight complex in plasma. Plasma IgG titers were not correlated with cognitive status except that AD and ADdiabetic participants were significantly cognitively impaired relative to the two non-AD groups. There also was no significant correlation between IgG titers and subject age, except that there was a trend for a negative slope for the AD participants and a positive slope for the control participants. In keeping with the human data, we also report that chemicallyinduced diabetes in rats was associated with high levels of AGEs, anti-RAGE-like IgGs, and anti-Aβ42-like IgGs. For non-diabetic rats, there was a clear age-dependency regarding the magnitude of the IgG levels. These data support the concept of an interrelationship between diabetes and AD. For both diseases one underlying contributing factor to cytotoxicity could be the development of an autoimmune response triggered by the presence of AGEs and amyloid peptides.
Export Options
About this article
Cite this article as:
Mruthinti Shyamala, Schade F. Rosann, Harrell U. Dean, Gulati K. Nidhi, Swamy-Mruthinti S., Lee P. Gregory and Buccafusco J. Jerry, Autoimmunity in Alzheimers Disease as Evidenced by Plasma Immunoreactivity Against RAGE and Aβ42: Complication of Diabetes, Current Alzheimer Research 2006; 3 (3) . https://dx.doi.org/10.2174/156720506777632899
DOI https://dx.doi.org/10.2174/156720506777632899 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer’s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oxidized-LDL and Paraoxonase-1 As Biomarkers of Coronary Artery Disease in Patients with Sleep-Disordered Breathing
Current Medicinal Chemistry Phosphatidylinositol 3-Kinase Isoforms as Novel Drug Targets
Current Drug Targets Exosomes and Exosomal microRNAs in Age-associated Stroke
Current Vascular Pharmacology Antiplatelet and Antithrombin Strategies in Acute Coronary Syndrome: State-Of-The-Art Review
Current Cardiology Reviews Malaria and artemisinin derivatives: an updated review
Mini-Reviews in Medicinal Chemistry From Nature to Drug Discovery: The Indole Scaffold as a ‘Privileged Structure’
Mini-Reviews in Medicinal Chemistry Hydrochlorothiazide vs. Chlorthalidone as the Optimal Diuretic for the Management of Hypertension
Current Pharmaceutical Design Mevalonate Cascade and Neurodevelopmental and Neurodegenerative Diseases: Future Targets for Therapeutic Application
Current Molecular Pharmacology Intradialytic Hypertension: An Under-recognized Cardiovascular Risk Factor. What is the Evidence?
Current Hypertension Reviews Molecular Biological Roles of Ursolic Acid in the Treatment of Human Diseases
Current Bioactive Compounds Metabolism-based Drug-drug Interactions in Patients with Chronic Respiratory Diseases: A Review Focusing on Drugs Affecting the Respiratory System
Current Drug Metabolism Monocytes, Macrophages and Other Inflammatory Mediators of Abdominal Aortic Aneurysm
Current Pharmaceutical Design MCP-1/CCL2 as a Therapeutic Target in Myocardial Infarction and Ischemic Cardiomyopathy
Inflammation & Allergy - Drug Targets (Discontinued) Lactose and Casein Cause Changes on Biomarkers of Oxidative Damage and Dysbiosis in an Experimental Model of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Statins in Bacteremia, Sepsis and Pneumonia: Have We Found the Holy Grail?
Recent Patents on Inflammation & Allergy Drug Discovery Potential Role of Endothelin in Early Vascular Aging
Current Hypertension Reviews The Promise of Plant Polyphenols as the Golden Standard Skin Anti-Inflammatory Agents
Current Drug Metabolism Detection of Klebsiella Antibodies and HLA-B27 Allelotypes Could be Used in the Early Diagnosis of Ankylosing Spondylitis with a Potential for the Use of “Low Starch Diet” in the Treatment
Current Rheumatology Reviews The Molecular Targets of Swertiamarin and its Derivatives Confer Anti- Diabetic and Anti-Hyperlipidemic Effects
Current Drug Targets The Role of the Osteoprotegerin/RANKL/RANK System in Diabetic Vascular Disease
Current Medicinal Chemistry